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Summary Patients hospitalised for exacerbations contribute significantly to the
total chronic obstructive pulmonary disease (COPD)-related healthcare costs. This
study aimed to determine the resource use and costs of exacerbations by
exacerbation-severity and to identify risk factors for hospitalisation.
Exacerbations and the details of all associated healthcare utilisation were
recorded as part of a prospective cost-effectiveness analysis linked to two
randomised controlled trials comparing tiotropium with ipratropium in 519 patients
with stable COPD at study entry in the Netherlands and Belgium. Exacerbation-
severity was rated by the physician. A Cox proportional hazards analysis was
performed to identify independent risk factors of hospitalisation. Covariates that
entered this analysis were smoking status, pack-years, body mass index, number of
concomitant diseases, number of concomitant medications, use of inhaled steroids,
physician visits prior to trial, FEV1% predicted, quality of life, baseline dyspnea index
(BDI) and treatment arm.
The mean number of exacerbations per patient was 0.70 (95%-CI:0.60, 0.81).
About 10% of the exacerbations was severe, 47% moderate and 43% was mild. The
mean costs of these exacerbations were Euro 4007 (95%-CI:2004, 6011), Euro 579
(390, 768) and Euro 86 (49, 124), respectively. In addition to treatment arm, a body
mass index below 18.5 (RR:3.62), each additional concomitant diagnosis (RR:1.40)
and a decrease of 1 point in the baseline dyspnea index (RR:1.18) were significant
risk factors of hospitalisation.
Exacerbations that were associated with a hospitalisation accounted for 90% of the
total costs of exacerbations. Underweight, history of concomitant diseases and
increased dyspnea (BDI score) are factors that are likely to identify patients who are
at increased risk for generating high costs due to hospitalisation.
& 2004 Elsevier Ltd. All rights reserved.
Introduction
Chronic obstructive pulmonary disease (COPD) is a
highly prevalent, progressive degenerative respira-
tory disorder and a major cause of disability and
premature death. COPD morbidity and mortality
are increasing worldwide, due to increasing num-
bers of smokers, especially among women, and the
ageing of the population.1 Consequently, an alarm-
ing worldwide increase in the burden and costs of
COPD is projected for the foreseeable future.2–4
Many patients with COPD experience recurrent
exacerbations defined as episodes of worsening
breathlessness and/or wheeze, often accompanied
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by greater volume or purulence of sputum and
increased cough.5,6 Exacerbations contribute to a
more rapid decline in lung function,7 morbidity and
poorer quality of life8 as well as to increased
healthcare costs. They are the main reason for
COPD-related hospital admission, often after failed
initial exacerbation-therapy in the community.9
Estimates of the costs of exacerbations vary from
DM 297 (1998, Euros: 152) per exacerbation in a
German study,10 SEK 3136 (1999, Euros 344) in a
Swedish study11 to FF 3,289 (1994, Euros 501) in
a French study.12 The Swedish and German studies
show the costs to rise considerably with the
severity of the exacerbation. All of these studies
report that inpatient hospital care is the major cost
driver, responsible for 67%, 60% and 44% of the
exacerbation-related costs in the Swedish, French
and German study, respectively. The difference in
cost estimates between these studies is remarkable
and probably due to a variety of factors including
differences in definitions, patient populations,
treatment patterns and methods of data collection.
Moreover, the classification of exacerbation-sever-
ity is based on the resource use associated with
exacerbations, which of course reinforces the
association between severity and costs.
To reduce the costs of exacerbations, we need to
know more about risk factors for hospital admis-
sion, as this is the major cost driver. Such knowl-
edge would enable us to better target new
treatments and to minimise healthcare costs in
patients with COPD. The goal of the present study
was to determine the costs of exacerbations by
exacerbation-severity and identify risk factors
associated with high-cost exacerbations in patients
whose COPD was considered stable at entry into the
study. The classification of the severity of exacer-
bations was based on physicians’ assessments and a
very detailed record was kept of all relevant types
of healthcare utilisation associated with exacerba-
tions.
Methods
Design trials
This analysis was based on data from a prospective
cost-effectiveness analysis linked to two rando-
mised controlled double-blind trials comparing
18 mg tiotropium (Spirivas) inhalation capsules
administered once daily via the HandiHalers
device with ipratropium (Atrovents) 2 puffs of
20 mg administered four times daily via the metered
dose inhaler (MDI). The design and results of the
trials and the economic evaluation have been
published elsewhere.13,14 In brief, patients with a
diagnosis of COPD and a relatively stable airway
obstruction defined as an FEV1p65% of predicted
normal and FEV1p70% of FVC were randomised
to either tiotropium (n ¼ 344) or ipratropium
(n ¼ 175) in a ratio of 2:1. Patients were aged over
40 and had a smoking history of at least 10 pack-
years. Patients with a diagnosis of asthma were
excluded. One trial was performed in the Nether-
lands and the other in the Netherlands and
Belgium. Because the design of these trials was
identical the data were combined. After a 2-week
run-in period, patients were seen at regularly
scheduled follow-up visits 1, 4, 7, 10, 13, 19, 26,
32, 29, 45 and 52 weeks after randomisation,
during which healthcare resource use, health out-
comes and adverse events, including COPD exacer-
bations were recorded. The trials were approved by
the medical ethics committees of the participating
hospitals, and all patients gave written informed
consent.
Exacerbations
All COPD exacerbations were recorded as adverse
events in the case report forms (CRF). A COPD
exacerbation was defined as a complex of respira-
tory symptoms (i.e. new onset or worsening of
more than one symptom such as cough, sputum,
dyspnea or wheeze) lasting for at least 3 days.
Exacerbations were classified in the CRF as either
mild, moderate or severe based on ratings by the
physician-investigator. A mild exacerbation was
defined as ‘awareness of a sign or symptom which
is easily tolerated’, a moderate exacerbation as ‘an
exacerbation causing discomfort enough to cause
interference with usual activity’ and a severe
exacerbation was defined as ‘an exacerbation that
was incapacitating or causing inability to do work or
usual activity’.
Resource use and costs
A very detailed record was kept of all relevant
types of healthcare utilisation associated with
exacerbations, including: hospital admissions and
length of stay (ICU and non-ICU days), emergency
room visits, visits to respiratory physicians, GPs and
other healthcare providers that were not scheduled
in the clinical trial protocol, ambulance transpor-
tations, tests, rescue medication (salbutamol MDI,
1 puff¼ 100mcg) and other respiratory medica-
tions including antibiotics. When a COPD exacer-
bation was associated with a hospital admission this
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was recorded by the physician-investigator in the
CRF. At the end of the trial, all hospital admissions
were verified using hospital chart audit. When
hospitalised patients withdrew from the study
before they were discharged, the total length of
hospital stay was taken into account, including the
days after withdrawal. To calculate the medication
costs during exacerbations, we only included those
new respiratory medications that patients started
to take during the exacerbation and the dose
increases of respiratory medication that patients
were already taking before the onset date of the
exacerbation. Costs of new medications and dose
increases were calculated until the end date of the
prescription, with a maximum duration of 3 weeks
after the end date of the exacerbation in case the
new medication or new dose was continued. All
changes in dose during the exacerbation and the 3
weeks thereafter were taken into account.
Costs were calculated by multiplying the re-
source use related to exacerbations with unit costs
for the Netherlands (year 2001 prices).14 All
healthcare costs were included in the analysis and
calculated from the societal perspective. This
implies that all healthcare costs were taken into
account, regardless of whether they were borne by
government, private or public insurers, or the
patients and their families. In addition, unit costs
of the major cost drivers were based on estimates
of real resource use and not reimbursements.
Caregiver and productivity costs were not included.
Statistical analyses
Differences in baseline characteristics between
patients with and without exacerbations were
tested using t-tests for continuous variables and
chi-square tests for categorical variables. Boot-
strapping was used to determine 95% confidence
intervals around estimates of the duration, re-
source use and costs of exacerbations by severity.
The univariate association between baseline-vari-
ables and time to hospital admission were investi-
gated using log-rank tests. In case of continuous
variables, the median was used to create two
groups. Except for the BMI which was dichotomised
using the underweight criterion of 18.5.15 The
independent contribution of each potential risk
factor for hospitalisation was investigated using a
Cox proportional hazards analysis. Covariates se-
lected for the Cox analysis included: BMI
(0 :X18:5; 1 :o18:5), smoking status (0: ex-smo-
ker, 1: current smoker) and smoking pack-years,
number of concomitant diagnoses, number of
unscheduled physician visits prior to trial, use of
inhaled corticosteroids (0: no steroid use, 1: steroid
use) and number of concomitant medications,
baseline dyspnea index (BDI), FEV1% predicted
normal and the total score of the St. George’s
Respiratory Questionnaire (SGRQ). To verify
whether the associations between FEV1% predicted
and hospitalisation and the SGRQ total score and
hospitalisation became stronger when not only the
baseline values of these parameters were consid-
ered, we also performed an analysis in which FEV1%
predicted and the SGRQ total score were entered as
time dependent variables (i.e. an analysis based on
four strata of 3 months in which the FEV1 and SGRQ
measurements of the beginning of each stratum
were used). The Cox regressions were performed
with SPSS 11.0.1, using a backward stepwise
elimination procedure, selecting covariates with a
P-value ( 0:1: Variable independency was checked
by inspection of the correlation matrix. The
assumption of proportional hazards was checked
using a log-minus-log survival plot.
Results
Patients
Five hundred and thirty-five patients were rando-
mised of whom 519 had completed at least one visit
after randomisation. The baseline characteristics
of these 519 patients are shown in Table 1,
comparing patients with and without exacerba-
tions. The mean age of patients was 64 (SD 8) years
and 440 (85%) were male. Compared to patients
who had no exacerbations during the observation
period, patients who experienced at least one
exacerbation had significantly more concomitant
diagnoses (2.6 versus 2.2, P ¼ 0:007), higher use of
concomitant medications (2.9 versus 2.4,
P ¼ 0:007), lower FEV1% predicted (37.5 versus
41.2, P ¼ 0:001), worse health status (SGRQ total
score 48.7 versus 42.3, Po0:001) and more dyspnea
at baseline (BDI 6.7 versus 7.5, P ¼ 0:001).
Exacerbations
The 519 patients included in the current analysis
experienced 364 exacerbations. The mean number
of exacerbations was 0.70 (95% CI:0.60–0.81) per
patient and the mean number of exacerbation-days
was 11.32 (95% CI:9.34–13.30) per patient. After
correcting for differences in the duration that
patients remained in the study, the mean number
of exacerbations and exacerbation-days per pa-
tient-year were 0.80 and 12.97, respectively. About
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40% (n ¼ 207) of the 519 patients experienced at
least one exacerbation. The maximum number of
exacerbations in one patient was nine. The mean
duration of an exacerbation was 16.1 (95% CI:14.8–
17.6) days and the median duration was 12 days.
About 10% (n ¼ 36) of the exacerbations was
severe, 47% (n ¼ 173) moderate and 43%
(n ¼ 155) mild. The mean (median) duration of a
severe exacerbation was 25.3 (20) days (95%
CI:19.8–31.3), which was significantly longer than
the mean (median) duration of moderate and mild
exacerbations which were 16.6 (13) days (95%
CI:14.7–18.9) and 13.5 (11) days (95% CI:12.1–
15.1), respectively.
Resource use during exacerbations
Healthcare resource use data were complete for
350 of the 364 exacerbations (Table 2). Of the
severe exacerbations, 78% (n ¼ 28) was associated
with at least one hospital admission and 25% (n ¼ 9)
with at least one ER-visit. Of the moderate
exacerbations, 16% (n ¼ 26) was associated with a
hospital admission and 5% (n ¼ 8) with a visit to the
ER. Only in 1 case, a patient was hospitalised when
experiencing an exacerbation rated as mild by the
clinician. In case of a hospitalisation, the mean
(median) length of stay was 15.4 (14) (95% CI: 12.5–
19.2) days for a severe exacerbation and 11.8 (10)
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Table 2 Mean (sd) resource use per exacerbation.
Severity of exacerbation
All Severe Moderate Mild
(n ¼ 350) (n ¼ 36; 10.3%) (n ¼ 164; 46.9%) (n ¼ 150; 42.8%)
Days general/pulmonary ward 2.05 (5.26) 11.08 (7.89) 1.87 (4.85) 0.08 (0.98)
Days intensive care unit 0.09 (1.30) 0.86 (4.03) F F
Visits to respiratory physician 0.39 (0.73) 0.82 (1.32) 0.37 (0.61) 0.31 (0.61)
Visits to general practitioner 0.66 (1.03) 0.70 (0.94) 0.78 (1.08) 0.52 (0.99)
Visits to other healthcare provider 0.29 (2.50) 0.50 (2.33) 0.44 (3.42) 0.09 (0.67)
Visits to emergency room 0.05 (0.22) 0.25 (0.44) 0.05 (0.22) 0.01 (0.08)
Puffs of salbutamol rescue medication 72 (117) 143 (168) 73 (137) 53 (62)
Ambulance services 0.06 (0.31) 0.31 (0.75) 0.07 (0.27) F
Table 1 Characteristics of the study population at baseline (N ¼ 519)n.
Without exacerbationsw With exacerbations
N ¼ 312 N ¼ 207
Age 63.9 (8.3) 63.9 (8.1)
Males: no. (%) 268 (86) 172 (83)
Current smokers: no. (%) 134 (43) 96 (46)
Smoking history in pack years 33.4 (17.5) 33.9 (17.4)
Duration of COPD in years 11.1 (10.0) 12.1 (9.8)
No. of concomitant diagnoses 2.2 (1.4) 2.6 (1.5)z
No. of physician visits 3 months prior to trial 0.51 (2.9) 0.49 (2.6)
Body mass index (BMI) 24.8 (3.7) 25.1 (4.0)
No. of concomitant medications 2.4 (1.7) 2.9 (2.0)z
Use of inhaled steroids (y/n): no. (%) 244 (78) 164 (79)
Prebronchodilator FEV1 (liters) 1.25 (0.44) 1.09 (0.38)
z
Prebronchodilator FEV1 (% of pred.) 41.2 (12.3) 37.5 (11.6)
z
SGRQ total scorey 42.3 (16.9) 48.7 (16.4)z
Baseline dyspnea index (BDI) 7.5 (2.4) 6.7 (2.6)z
nMean (standard deviation) unless stated otherwise.
wP-value of the difference between patients with and without exacerbations o0:05:
zP-value of the difference between patients with and without exacerbations o0:01:
ySGRQ: St. George’s Respiratory Questionnaire.
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(95% CI: 9.8–14.1) for a moderate exacerbation.
The mean (median) number of unscheduled visits
was 2.3 (2) (95% CI:1.5–3.4) in severe exacerba-
tions and 1.6 (1) (95% CI:1.2–2.3) in moderate
exacerbations. All resource use other than GP-visits
was highest in severe exacerbations.
Cost of exacerbations
Table 3 presents the unit costs of the major
resource use items and the mean costs per
exacerbation by severity. The mean cost of an
exacerbation was Euro 720 (95% CI:515–1003). The
mean costs of severe exacerbations were Euro 4007
(95% CI:2551–6366), which was approximately 7
times higher than the mean costs of moderate
exacerbations (Euro 579, 95% CI:407–769) and 47
times as high as the costs of mild exacerbations
(Euro 86, 95% CI:60–130). The median costs of mild,
moderate and severe exacerbations were Euro 49,
86 and 2824, respectively. About 86% of the costs of
severe exacerbations resulted from inpatient hos-
pital days and 6% from diagnostic tests. Despite the
relatively low percentage of hospitalisations in
moderate exacerbations (16%), hospitalisation
costs accounted for 71% of the costs of moderate
exacerbations. In mild exacerbations, concomitant
medications were the main cost driver and
accounted for 37% of the total costs whereas
unscheduled visits accounted for 33% of the total
costs. Costs of concomitant medications varied
considerably with exacerbation severity and ranged
from Euro 158 (95% CI :90–249) for a severe
exacerbation to Euro 32 (95% CI:27–37) for a mild
exacerbation. Fig. 1 shows the costs of medications
during exacerbations. About 58% of these costs
were due to antibiotics and about 22% due to
systemic corticosteroids.
Fig. 2 shows the relationship between the
proportion of exacerbations and the proportion of
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Table 3 Mean (SD) costs per exacerbation in 2001 Euro.
Severity of exacerbation
Unit costs All Severe Moderate Mild
per day/visit (n ¼ 350) (n ¼ 63) (n ¼ 176) (n ¼ 111)
General/pulmonary ward 222 454 (1167) 2456 (1748) 413 (1074) 18 (217)
Intensive care unit 1146 101 (1493) 987 (4617) F F
Visits respiratory physician 52 20 (38) 43 (69) 19 (32) 16 (32)
Visits to general practitioner 18 12 (18) 12 (16) 14 (19) 9 (17)
Visits to ohcpn 19 6 (48) 10 (44) 8 (65) 2 (12)
Visits to emergency room 98 5 (22) 25 (43) 5 (21) 1 (8)
Rescue medication 2 (3) 4 (5) 2 (4) 1 (2)
Respiratory medications 52 (95) 158 (244) 46 (52) 32 (32)
Diagnostic tests 53 (167) 236 (340) 54 (157) 7 (20)
Ambulance services 16 (79) 77 (189) 17 (69) F
Total healthcare costs 720 (2354) 4007 (5922) 579 (1227) 86 (233)
nOHCP: Other healthcare provider.
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Figure 1 Costs of medication per exacerbation in Euros
dashed bars: antibiotics, white bars: corticosteroids,
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Figure 2 Cumulative costing curve of the costs per
exacerbation.
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total costs of exacerbations. The curve has a steep
slope at the beginning, indicating that a small
number of exacerbations accounted for a large part
of the total costs. The 16% of exacerbations that
were associated with a hospitalisation accounted
for approximately 90% of the total costs of
exacerbations. About half of these exacerba-
tions were rated severe and the other half was
rated moderate. The total costs of all exacerba-
tions accounted for approximately 34% of the
total respiratory-related healthcare costs that
were calculated in the original economic evalua-
tion.14
Factors associated with time to hospital
admission
Table 4 shows the univariate association between
patient characteristics and the Kaplan–Meier esti-
mate of the cumulative proportion of patients with
hospitalisation. A low BMI, a high number of
concomitant diagnoses, a high number of respira-
tory medications, a low BDI score and assignment to
the ipratropium treatment arm were significantly
associated with an increased risk of hospitalisation.
The largest differences in the proportions of
patients with hospitalisation were found between
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Table 4 Univariate analysis of factors associated with time to hospitalisation.
Predictor variable Subgroupsn Cumulative proportion of
patients with
hospitalisationw
P-value (log-rank test)
Smoking status ex smoker 0.09
smoker 0.14 0.094
Smoking pack years o30 0.08
430 0.16 0.058
Body mass index (BMI) o18.5 0.37
418.5 0.10 o0.001
No. of concomitant
diagnoses
o2 0.06
42 0.19 o0.001
No. of concomitant
medications
o2 0.07
42 0.16 0.019
Use of inhaled steroids
(y/n)
No steroid use 0.11
steroid use 0.11 0.690
No. of physician visits 3
mo prior to trial
o1 0.11
41 0.07 0.760
FEV1 (% of predicted
normal)
o39 0.13
439 0.10 0.070
St. George’s Respiratory o44 0.08
Questionnaire total score 444 0.15 0.066
Baseline dyspnea index o7 0.17
47 0.06 0.004
Treatment group
assignment
Ipratropium 0.14
tiotropium 0.10 0.048
nIn case of continuous variables the median was used to create two groups. BMI was split into two groups using the underweight
criterion of 18.5(15).
wCumulative proportions based on Kaplan–Meier curves.
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patients with a history of more or less than two
concomitant diagnoses (0.19 versus 0.06) and
between patients with a BMI below or above 18.5
(0.37 versus 0.10).
In the Cox proportional hazards analysis BMI,
treatment group, the number of concomitant diag-
noses at baseline and BDI were independent risk
factors of hospital admission (Table 5). The risk of
hospitalisation for patients with a BMI below 18.5 was
3.6 times higher than for patients without under-
weight. A 1-unit decrease (¼ increased dyspnea) in
the BDI increased the risk of hospitalisation by 18.2%
and each additional diagnosis increased the hazard
rate by 40.4%. Patients treated with tiotropium
experienced less than half the hospitalisation risk of
patients treated with ipratropium. The correlation
matrix showed that the Pearson correlation coeffi-
cients between the 11 variables that entered the
model at the start were always less than 0.37, except
for the BDI and the SGRQ. These two variables were
highly correlated (Pearson R: 0.651; Po0:001). When
the baseline values of both were entered, the BDI
proved to be a more powerful predictor. When the
BDI was left out, the SGRQ demonstrated an
increased risk of hospitalisation of 8% for each 4
units increase (¼worsening) in the SGRQ total score.
Entering FEV1% predicted and the SGRQ as time-
dependent variables did not improve the model, nor
did adding the SGRQ domains instead of the SGRQ
total score. Excluding treatment arm as a covariate
did not lead to a statistical significant contribution of
other risk factors, while the other significant
covariates in the model were hardly affected.
Discussion
About 40% of the patients whose COPD was judged
to be stable at entry into the current study
experienced at least 1 exacerbation and the mean
number of exacerbations per patient-year was
0.80. The mean duration of an exacerbation was
16 days. There was a wide variation in the costs
of exacerbations, ranging from Euro 4007 for a
severe exacerbation to Euro 579 and Euro 86 for
moderate and mild exacerbations. About 16% of the
exacerbations was associated with a hospital
admission and these exacerbations were responsi-
ble for about 90% of the total costs of exacerba-
tions. A BMI below 18.5, a higher number of
concomitant diagnoses and increased dyspnea (a
low BDI score) at baseline were significantly
associated with an increased risk of hospitalisation.
In addition, treatment with tiotropium reduced the
risk of hospitalisation by 57% compared to ipratro-
pium.
The definition of exacerbation severity was based
on physicians’ assessments of the extent to which
an exacerbation interfered with the ability to
perform usual activities. Previous studies have used
health care resource use to define severity. In such
a classification, severe exacerbations are often
defined as those associated with a hospital admis-
sion, moderate exacerbations as those associated
with an outpatient visit with or without the
prescription of an oral steroid or an antibiotic,
and mild exacerbations as those that are primarily
self-managed. We did not adopt this definition
because treatment patterns are likely to vary
across settings. An exacerbation that is severe in
one country might not be rated as severe in another
country because the countries may use different
criteria to hospitalise a COPD patient. However,
when we applied this definition to our study, we
observed a further increase of the difference in
costs between severe exacerbations (Euro 4117) on
the one hand and moderate (Euro 123) and mild
exacerbations (Euro 29) on the other hand, signify-
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Table 5 Final Cox proportional hazards analysis of the time to hospitalisation for COPD exacerbation.
Predictor variablen Increment Relative risk 95% CI
Body mass index (BMI) 0 ¼418:5 3.62 1.50; 8.71
1 ¼o18:5
No. of concomitant diagnoses Per additional diagnosis 1.40 1.15; 1.72
Baseline dyspnea index per unit decrease 1.18 1.04; 1.34
Treatment group assignment 0 ¼ ipratropium 0.43 0.23; 0.78
1 ¼ tiotropium
nVariables entered into the full model: smoking status, smoking pack years, BMI, no. of concomitant diagnoses, no. of
concomitant medications, use of inhaled corticosteroids, no. of physician visits 3 months prior to the trial, FEV1% predicted,
SGRQ total score, Baseline Dyspnea Index, treatment group. Backward stepwise elimination procedure (Po0:10).
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ing the large impact of hospitalisations on the cost
per exacerbation.
The Cox proportional hazard analysis showed
that, apart from treatment group, a low BMI, a
higher number of concomitant diagnoses and
dyspnea measured with the BDI were significantly
associated with hospitalisation. The BDI was a
better predictor than FEV1, which is generally
considered to be the most important marker of
COPD severity. Even when BDI was removed from
the model, FEV1 was not identified as an indepen-
dent risk factor for hospital admission. This finding
is in line with other studies, which reported that
dyspnea was predictive of (severe) re-exacerba-
tions8 and mortality.16 Dyspnea might ‘‘reflect more
comprehensive information than airway obstruc-
tion’’17 and might be a marker of COPD severity
that is at least as important as FEV1. Especially
when dyspnea is measured with an instrument like
the BDI, which also covers the functional aspects of
breathlessness as assessed by the patient. This
probably explains part of the interchangeability
between the BDI and the SGRQ. The SGRQ has been
shown to predict hospital admission before.18 When
BDI was removed from the model, the SGRQ
became a significant risk factor of hospitalisation,
whereas the coefficients of the other significant
covariates were hardly affected. When both were
entered, the BDI appeared to be more powerful.
Even when the SGRQ was entered as a time-
dependent variableFto study whether quality of
life in the period before the hospitalisation is a
better predictor than quality of life at base-
lineFthe BDI continued to show a stronger
association with hospital admission than the SGRQ.
Strengths of the current study were the prospec-
tive and detailed collection of data about exacer-
bations and resource use. It should be noticed,
however, that these data were collected in a
clinical trial setting. As in most clinical trials,
patients were monitored closer than in daily
practice. There is always a risk that the regularly
scheduled trial visits substitute visits that would
have occurred if the trial had not taken place. On
the other hand, patients in a trial are often more
strongly encouraged to contact the physician when
their condition deteriorates. The trial was per-
formed in a population of stable COPD patients with
less comorbidity than in the average COPD popula-
tion. Even in this population, we found that
exacerbations accounted for approximately 34% of
the total respiratory-related healthcare costs.14
This 34% compares well to a Swedish observational
study that applied very few selection criteria. In
that study it was found that approximately 35–45%
of the costs of COPD treatment were due to
exacerbations.11 These percentages are very dif-
ferent from a number of database-studies reporting
costs in the US.19,20 Although these studies did not
explicitly relate costs to exacerbations, it was
estimated that approximately 70% of the costs of
treating patients with COPD were due to hospita-
lisations. This higher percentage is probably re-
lated to the higher unit costs of an inpatient
hospital day in the US, but may also be due to
differences in treatment patterns and study design.
The data at least suggest that there are large
differences in the costs of treating COPD across
countries, which may have large impacts on the
cost-effectiveness of (new) treatments in COPD.
Any treatment that successfully prevents severe
exacerbations and costly hospitalisations is likely to
be most cost-effective in countries with high costs
of hospitalisation.
In conclusion, many patients whose COPD is
judged to be stable experience exacerbations.
According to our definition of severity, roughly
40% of the exacerbations was mild, 50% was
moderate and 10% was severe. Costs of severe
exacerbations were approximately 7 and 47 times
as high as the costs of moderate and mild
exacerbations, respectively. Exacerbations that
were associated with a hospitalisation accounted
for 90% of the total costs of exacerbations. A low
BMI, a history of concomitant diseases and in-
creased dyspnea are factors that are likely to
identify patients who are at increased risk of
generating high costs as a result of hospitalisation.
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